In a continuing trend by legislators across the country to "mandate" coverage and access when the marketplace has moved on from these issues while focusing on the cost of healthcare, the California Department of Managed Care issued rules requiring HMOs to provide broad coverage of medically necessary prescription drugs.
NATIONAL REPORTS-In a continuing trend by legislators across the country to "mandate" coverage and access when the marketplace has moved on from these issues while focusing on the cost of healthcare, the California Department of Managed Care issued rules requiring HMOs to provide broad coverage of medically necessary prescription drugs.
"Many states, Ohio included, have instituted administrative positions that dictate no further passage of coverage 'mandates' without proper actuarial review and analysis to determine the cost of such mandates and the impact that these increased costs will have on the ability of the consumer and employers to afford healthcare coverage," according to the Ohio Association of Health Plans' Board Chairman Bill Epling, also regional vice president and CFO, The Health Plan/HomeTown Health Network in Massillon, Ohio.
MARKET MOVES ON "Access and any-willing-provider arguments are topics of the 1990s that have been surpassed in the market by: 'How can we afford to offer healthcare benefits to our employees?'" Epling says. "Unfortunately, many state legislative bodies are still operating under the old perceptions that the health insurance industry must be fixed to save the consumer and the physician."
At face value, Jack McClurg, CEO, HealthTrans, Greenwood Village, Colo., does not believe that it is in the best interest of a patient, health insurance consumer or the employer to have government restrict the ability of plans to negotiate with drug manufacturers.
"If every drug that is marketed must be made available without weighing efficacy and cost, the cost for drugs will go unchecked," McClurg says. "Currently the most effective method to make patients and physicians aware of costs is through variable copays which don't deny a drug therapy of choice, but shifts the cost for inefficient therapies."
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
New PTSD Treatment Shows Promise with Brexpiprazole, Sertraline Combination
December 24th 2024Currently, the only medications approved by the FDA for PTSD are the selective serotonin reuptake inhibitors (SSRIs) sertraline and paroxetine. However, these medications don’t work for everyone.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
How the Contact Center Can Be a Driver of VBC Success
December 23rd 2024Historically, healthcare organizations have considered the contact center to be a cost center, a communications platform for conveying information to patients and plan members. Today, however, AI-enabled contact centers can be drivers of value, especially in a value-based care environment.
Read More